ReACH

ReACH collects and manages systematic clinical and longitudinal data for pediatric patients with achondroplasia (ACH) to support research on FGFR3-mediated disease mechanisms and evaluation of therapies such as FGFR3 inhibitors (e.g., vosoritide).

Key Features:

• Data collection and cohort scope: Established in 2015 across the Czech Republic and Slovakia, the registry enrolls pediatric ACH patients aged three months to fourteen years and aims to represent approximately 60% of the anticipated regional ACH population.
• Clinical trial candidate identification: The database facilitates identification of candidates for trials of FGFR3 inhibitors, including vosoritide, emphasizing early intervention prior to epiphyseal growth plate closure.
• Longitudinal growth monitoring: The registry contains 89 measurements per patient including heights, weights, and other clinical parameters and computes individual average growth rates, which are consistently observed in the lower decile relative to age norms.
• Comprehensive health phenotyping: ReACH records neurological, orthopedic, and otolaryngological (ORL) diagnoses alongside growth metrics to support multifaceted clinical assessment.
• Paternal age analysis: The registry documents a significant paternal age effect, noting that over half of fathers were older than the general average paternal age at conception.
• Database infrastructure: Patient data are entered into the online TrialDB system and stored in an Oracle 9i database following informed consent.

Scientific Applications:

• Disease pathophysiology: Enables study of FGFR3-related mechanisms underlying ACH by linking clinical phenotypes to growth trajectories and comorbidities.
• Treatment efficacy evaluation: Provides longitudinal outcome data to assess effects of FGFR3 inhibitors such as vosoritide on growth and clinical endpoints.
• Clinical trial recruitment: Supports selection of age- and phenotype-appropriate pediatric candidates for interventional studies, particularly before epiphyseal growth plate closure.
• Patient management and prognosis: Informs growth-rate–based monitoring and anticipatory management of neurological, orthopedic, and ORL complications.
• Genetic epidemiology: Facilitates analysis of demographic factors such as the documented paternal age effect in ACH incidence.

Methodology:

Clinical data are entered into TrialDB, stored in an Oracle 9i database, and longitudinal measurements are used to calculate individual average growth rates.